Valvular & structural heart diseaseCohort study
Contemporary Outcomes and Trends for the Transseptal Mitral Valve-in-Valve Procedure Using Balloon Expandable Transcatheter Valves in the United States
- Registry-based cohort study
- multicentre
- prospective
Authors' conclusion
This multicenter, prospective study reports excellent procedural outcomes, acceptable 1-year mortality rates, and a significant improvement in quality of life for patients undergoing transseptal MViV in the contemporary era.
Study context
- Population
- Patients undergoing transseptal SAPIEN 3/SAPIEN 3 Ultra mitral valve-in-valve (mitral valve in valve (MViV)) for degenerated bioprosthesis, Society of Thoracic Surgeons (STS)/ACC TVT Registry, 2015 to September 2022
- Participants
- 4,243 patients · 455 sites
- Outcome
- All-cause mortality
- Follow-up
- 1 year
Main finding
As reported in the abstract
1-year all-cause mortality
13.4%
Observational data: associations, not effects.
Secondary outcomes
All-cause mortality, in-hospital and 30-day
- In-hospital mortality
- 3.2%
- 30-day mortality
- 4.3%
NYHA I/II and KCCQ score, baseline to 1 year
- NYHA I/II
- 18% to 87%
- KCCQ score
- 38 to 78
- P<0.0001 for both
In-hospital mortality by STS risk
- Low risk (STS<4)
- 0.4%
- Intermediate risk (STS, 4-8)
- 1.9%
Temporal trend in mortality, 2015 to 2022
- In-hospital mortality, reduced trend
- P = 0.0005
- 30-day mortality, reduced trend
- P = 0.004
- 1-year mortality, reduced trend
- P = 0.01
Safety
MVARC technical success
- Technical success
- 96.6%
- Procedural complications were low
Original publication
Contemporary Outcomes and Trends for the Transseptal Mitral Valve-in-Valve Procedure Using Balloon Expandable Transcatheter Valves in the United States. Circulation. Published 5 August 2024. doi:10.1161/circulationaha.124.068847
Summarised from the published abstract; every number is checked against it